Medical Versus Surgical Management of Moderate Mitral Regurgitation Following Percutaneous Coronary Intervention

Withdrawn before enrolling · Phase 1/Phase 2

Conditions studied: Myocardial Infarction, Mitral Regurgitation

In brief

The pilot prospective randomized trial is designed to determine the safety and feasibility of enrolling patients to surgically correct residual Mitral Regurgitation (MR) following Percutaneous Coronary Intervention (PCI) for Myocardial Infarction (MI) verses ongoing medical management of MR. The investigators hypothesize that if moderate MR is corrected in this patient subset, the patients will have improved outcomes as measured by decreased number of major adverse cardiac events, including death, congestive heart failure requiring hospitalization, atrial fibrillation, deterioration of New York Heart Association (NYHA) functional status and improved quality of life.

Key facts

Study ID

NCT01156441

Run by

Southern Illinois University

People needed

0

Starts

2010-07-01

Expected to finish

2014-06-01

Last updated by the study team

2014-06-16

Who can join

Age: 19 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients who have undergone PCI for first acute MI (index MI) since 7/1/09 at MMC and STJ
• documented moderate mitral regurgitation on follow up echocardiography six or more weeks after PCI procedure
• English speaking

You may not qualify if…

• CABG after PCI for acute MI
• History of previous MI prior to index MI
• History of previous PCI or CABG prior to index PCI
• EF <30 % on the echocardiogram at 6 weeks after PCI for MI

Where it is running

• Southern Illinois University School of Medicine — Springfield, Illinois, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.